Comparative Pharmacology
Head-to-head clinical analysis: LIORESAL versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIORESAL versus RELA.
LIORESAL vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant